Yonsei University

About: Yonsei University is a education organization based out in Seoul, South Korea. It is known for research contribution in the topics: Population & Cancer. The organization has 50162 authors who have published 106172 publications receiving 2279044 citations. The organization is also known as: Yonsei.

Fairness and load balancing in wireless LANs using association control

Abstract: The traffic load of wireless LANs is often unevenly distributed among the access points (APs), which results in unfair bandwidth allocation among users. We argue that the load imbalance and consequent unfair bandwidth allocation can be greatly reduced by intelligent association control. In this paper, we present an efficient solution to determine the user-AP associations for max-min fair bandwidth allocation. We show the strong correlation between fairness and load balancing, which enables us to use load balancing techniques for obtaining optimal max-min fair bandwidth allocation. As this problem is NP-hard, we devise algorithms that achieve constant-factor approximation. In our algorithms, we first compute a fractional association solution, in which users can be associated with multiple APs simultaneously. This solution guarantees the fairest bandwidth allocation in terms of max-min fairness. Then, by utilizing a rounding method, we obtain the integral solution from the fractional solution. We also consider time fairness and present a polynomial-time algorithm for optimal integral solution. We further extend our schemes for the on-line case where users may join and leave dynamically. Our simulations demonstrate that the proposed algorithms achieve close to optimal load balancing (i.e., max-min fairness) and they outperform commonly used heuristics.

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089)

Abstract: Purpose Maintenance therapy is associated with improved survival in patients with non–small-cell lung cancer (NSCLC), but few studies have compared active agents in this setting. AVAPERL evaluated the safety and efficacy of bevacizumab with or without pemetrexed as continuation maintenance treatment. Patients and Methods Patients with advanced nonsquamous NSCLC received first-line bevacizumab 7.5 mg/kg, cisplatin 75 mg/m2, and pemetrexed 500 mg/m2 once every 3 weeks for four cycles. Those achieving response or stable disease were randomly assigned at a ratio of 1:1 to maintenance bevacizumab 7.5 mg/kg or bevacizumab 7.5 mg/kg plus pemetrexed 500 mg/m2 once every 3 weeks until disease progression or unacceptable toxicity. The primary end point was progression-free survival (PFS) after random assignment. Results In total, 376 patients received induction treatment, 71.9% achieved disease control, and 67.3% were randomly assigned to maintenance therapy, with 125 and 128 receiving single-agent bevacizumab and ...